[Zurück]


Zeitschriftenartikel:

S. Diesner, C. Bergmayr, X. Wang, D. Heiden, S. Exenberger, F. Roth-Walter, P. Starkl, D. Ret, I. Pali-Schöll, F. Gabor, E. Untersmayr:
"Characterization of Vibrio cholerae neuraminidase as an immunomodulator for novel formulation of oral allergy immunotherapy.";
Clinical Immunology, 192 (2018), S. 30 - 39.



Kurzfassung englisch:
To improve current mucosal allergen immunotherapy Vibrio cholerae neuraminidase (NA) was evaluated as a novel epithelial targeting molecule for functionalization of allergen-loaded, poly(D,L-lactide-co-glycolide) (PLGA) microparticles (MPs) and compared to the previously described epithelial targeting lectins wheat germ agglutinin (WGA) and Aleuria aurantia lectin (AAL). All targeters revealed binding to Caco-2 cells, but only NA had high binding specificity to α-L fucose and monosialoganglioside-1. An increased transepithelial uptake was found for NA-MPs in a M-cell co-culture model. NA and NA-MPs induced high levels of IFN-γ and IL10 in naive mouse splenocytes and CCL20 expression in Caco-2. Repeated oral gavage of NA-MPs resulted in a modulated, allergen-specific immune response. In conclusion, NA has enhanced M-cell specificity compared to the other targeters. NA functionalized MPs induce a Th1 and T-regulatory driven immune response and avoid allergy effector cell activation. Therefore, it is a promising novel, orally applied formula for allergy therapy.

Schlagworte:
AAL; M-cell; Neuraminidase; Oral application; PLGA-microparticles; WGA


"Offizielle" elektronische Version der Publikation (entsprechend ihrem Digital Object Identifier - DOI)
http://dx.doi.org/10.1016/j.clim.2018.03.017

Elektronische Version der Publikation:
https://www.ncbi.nlm.nih.gov/pubmed/29608970


Erstellt aus der Publikationsdatenbank der Technischen Universitšt Wien.